

John D Lambris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6879050/publications.pdf>

Version: 2024-02-01

521
papers

49,256
citations

1296

112
h-index

2750

198
g-index

608
all docs

608
docs citations

608
times ranked

41710
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	3.2	51
2	Compstatins: the dawn of clinical C3-targeted complement inhibition. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 629-640.	4.0	31
3	Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research – 20 years of experience and future perspectives. <i>Seminars in Immunology</i> , 2022, 59, 101604.	2.7	5
4	Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
5	C3-targeted host-modulation approaches to oral inflammatory conditions. <i>Seminars in Immunology</i> , 2022, 59, 101608.	2.7	9
6	Complement component C3: A structural perspective and potential therapeutic implications. <i>Seminars in Immunology</i> , 2022, 59, 101627.	2.7	23
7	Considering innate immune responses in SARS-CoV-2 infection and COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 465-470.	10.6	14
8	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde. <i>Seminars in Immunology</i> , 2022, 60, 101640.	2.7	2
9	Emerging opportunities for C3 inhibition in the eye. <i>Seminars in Immunology</i> , 2022, 59, 101633.	2.7	5
10	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100936.	7.3	37
11	CD14 inhibition improves survival and attenuates thromboinflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 429-443.	1.9	16
12	Response to –Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19–. <i>Clinical Immunology</i> , 2021, 222, 108617.	1.4	0
13	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. <i>Nature Cancer</i> , 2021, 2, 218-232.	5.7	34
14	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera. <i>Frontiers in Immunology</i> , 2021, 12, 652242.	2.2	8
15	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. <i>Blood</i> , 2021, 138, 2106-2116.	0.6	23
16	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	25
17	Serum amyloid P component is an essential element of resistance against <i>Aspergillus fumigatus</i> . <i>Nature Communications</i> , 2021, 12, 3739.	5.8	18
18	Erythrocytes identify complement activation in patients with COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 321, L485-L489.	1.3	39

#	ARTICLE	IF	CITATIONS
19	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. <i>Nature Communications</i> , 2021, 12, 5456.	5.8	29
20	C3-targeted therapy in periodontal disease: moving closer to the clinic. <i>Trends in Immunology</i> , 2021, 42, 856-864.	2.9	27
21	Efficacy matters: broadening complement inhibition in COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e95.	2.2	6
22	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	47
23	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. <i>Journal of Immunology</i> , 2021, 207, 2828-2840.	0.4	5
24	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. <i>Haematologica</i> , 2020, 105, e57-e60.	1.7	17
25	Thirty-Eight-Negative Kinase 1 Is a Mediator of Acute Kidney Injury in Experimental and Clinical Traumatic Hemorrhagic Shock. <i>Frontiers in Immunology</i> , 2020, 11, 2081.	2.2	11
26	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. <i>Clinical Immunology</i> , 2020, 220, 108598.	1.4	191
27	Current understanding of periodontal disease pathogenesis and targets for host modulation therapy. <i>Periodontology 2000</i> , 2020, 84, 14-34.	6.3	173
28	Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. <i>Stem Cells Translational Medicine</i> , 2020, 9, 1585-1603.	1.6	36
29	Interaction of <i>Streptococcus pyogenes</i> with extracellular matrix components resulting in immunomodulation and bacterial eradication. <i>Matrix Biology Plus</i> , 2020, 6-7, 100020.	1.9	1
30	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. <i>Clinical Immunology</i> , 2020, 215, 108450.	1.4	252
31	Complement as a target in COVID-19?. <i>Nature Reviews Immunology</i> , 2020, 20, 343-344.	10.6	426
32	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. <i>Clinical Immunology</i> , 2020, 214, 108391.	1.4	16
33	Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 6151-6157.	3.9	580
34	Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement. <i>ELife</i> , 2020, 9, .	2.8	15
35	Complement C3 as a Target of Host Modulation in Periodontitis. , 2020, , 13-29.		1
36	Clinical promise of next-generation complement therapeutics. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 707-729.	21.5	253

#	ARTICLE	IF	CITATIONS
37	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. <i>Journal of Immunology</i> , 2019, 203, 853-863.	0.4	31
38	Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) Centroid Data Measured between 3.6 Å°C and 25.4 Å°C for the Fab Fragment of NISTmAb. <i>Journal of Research of the National Institute of Standards and Technology</i> , 2019, 124, 1-7.	0.4	3
39	“Stealth” corporate innovation: an emerging threat for therapeutic drug development. <i>Nature Immunology</i> , 2019, 20, 1409-1413.	7.0	7
40	Complement activation on neutrophils initiates endothelial adhesion and extravasation. <i>Molecular Immunology</i> , 2019, 114, 629-642.	1.0	15
41	C3 glomerulopathy “ understanding a rare complement-driven renal disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 129-143.	4.1	223
42	The Challenges and Promise of Complement Therapeutics for Ocular Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 1007.	2.2	76
43	Interlaboratory Comparison of Hydrogen-Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb. <i>Analytical Chemistry</i> , 2019, 91, 7336-7345.	3.2	44
44	New insights into the immune functions of complement. <i>Nature Reviews Immunology</i> , 2019, 19, 503-516.	10.6	281
45	Complementing the Cancer-Immunity Cycle. <i>Frontiers in Immunology</i> , 2019, 10, 774.	2.2	136
46	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. <i>Frontiers in Immunology</i> , 2019, 10, 406.	2.2	60
47	Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. <i>Frontiers in Immunology</i> , 2019, 10, 543.	2.2	47
48	Therapeutic targeting of the complement system. <i>Nature Reviews Drug Discovery</i> , 2019, , .	21.5	37
49	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. <i>Clinical Immunology</i> , 2019, 198, 102-105.	1.4	11
50	Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. <i>Haematologica</i> , 2019, 104, 919-928.	1.7	34
51	Reduced Terminal Complement Complex Formation in Mice Manifests in Low Bone Mass and Impaired Fracture Healing. <i>American Journal of Pathology</i> , 2019, 189, 147-161.	1.9	9
52	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. <i>Shock</i> , 2019, 51, 78-87.	1.0	34
53	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. <i>Frontiers in Immunology</i> , 2019, 10, 3029.	2.2	6
54	Innate immune responses to trauma. <i>Nature Immunology</i> , 2018, 19, 327-341.	7.0	377

#	ARTICLE	IF	CITATIONS
55	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. <i>Seminars in Hematology</i> , 2018, 55, 167-175.	1.8	32
56	Complement in cancer: untangling an intricate relationship. <i>Nature Reviews Immunology</i> , 2018, 18, 5-18.	10.6	279
57	Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression. <i>Cancer Research</i> , 2018, 78, 143-156.	0.4	94
58	Native state of complement protein C3d analysed via hydrogen exchange and conformational sampling. <i>International Journal of Computational Biology and Drug Design</i> , 2018, 11, 90.	0.3	6
59	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. <i>Cancer Cell</i> , 2018, 34, 531-533.	7.7	4
60	Short Leucine-Rich Proteoglycans Modulate Complement Activity and Increase Killing of the Respiratory Pathogen <i>Moraxella catarrhalis</i> . <i>Journal of Immunology</i> , 2018, 201, 2721-2730.	0.4	10
61	Intravascular complement activation on neutrophils initiates the inflammatory cascade. <i>Molecular Immunology</i> , 2018, 102, 198.	1.0	0
62	Safety profile after prolonged C3 inhibition. <i>Clinical Immunology</i> , 2018, 197, 96-106.	1.4	38
63	Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis. <i>Circulation</i> , 2018, 138, 1720-1735.	1.6	77
64	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1484-1487.	1.8	7
65	The Complement System Is Critical in Maintaining Retinal Integrity during Aging. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 15.	1.7	61
66	Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis. <i>Journal of Proteome Research</i> , 2018, 17, 3153-3175.	1.8	24
67	New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6153-6162.	2.9	23
68	The renaissance of complement therapeutics. <i>Nature Reviews Nephrology</i> , 2018, 14, 26-47.	4.1	305
69	Differential capacity for complement receptor-mediated immune evasion by <i>Porphyromonas gingivalis</i> depending on the type of innate leukocyte. <i>Molecular Oral Microbiology</i> , 2017, 32, 154-165.	1.3	17
70	Structural Implications for the Formation and Function of the Complement Effector Protein iC3b. <i>Journal of Immunology</i> , 2017, 198, 3326-3335.	0.4	21
71	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. <i>Trends in Immunology</i> , 2017, 38, 383-394.	2.9	31
72	Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects. <i>Journal of Immunology</i> , 2017, 198, 4846-4854.	0.4	58

#	ARTICLE	IF	CITATIONS
73	Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. <i>Acta Biomaterialia</i> , 2017, 58, 158-167.	4.1	17
74	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1326442.	2.1	48
75	Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F516-F532.	1.3	64
76	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. <i>Blood</i> , 2017, 129, 970-980.	0.6	119
77	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1041-1042, 19-26.	1.2	8
78	Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood. <i>Xenotransplantation</i> , 2017, 24, e12262.	1.6	13
79	Factor H IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen <i>Streptococcus pyogenes</i> . <i>Journal of Immunology</i> , 2017, 199, 3828-3839.	0.4	26
80	Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10948-10953.	3.3	77
81	Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. <i>Scientific Reports</i> , 2017, 7, 14061.	1.6	35
82	Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 6, 207-215.	1.8	33
83	Complement activation fragment C4a acts as effector molecule by signaling via protease-activated receptors 1 and 4. <i>Molecular Immunology</i> , 2017, 89, 130.	1.0	0
84	Complement C5a-induced Changes in Neutrophil Morphology During Inflammation. <i>Scandinavian Journal of Immunology</i> , 2017, 86, 143-155.	1.3	58
85	<i>Porphyromonas gingivalis</i> disturbs host commensal homeostasis by changing complement function. <i>Journal of Oral Microbiology</i> , 2017, 9, 1340085.	1.2	105
86	Novel mechanisms and functions of complement. <i>Nature Immunology</i> , 2017, 18, 1288-1298.	7.0	364
87	The effect of complement inhibition on erythrocyte destruction in AIHA. <i>Molecular Immunology</i> , 2017, 89, 203.	1.0	1
88	Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 643-651.	3.6	106
89	Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. <i>Frontiers in Immunology</i> , 2017, 8, 1586.	2.2	14
90	Coarse-Grained Conformational Sampling of Protein Structure Improves the Fit to Experimental Hydrogen-Exchange Data. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 13.	1.6	28

#	ARTICLE	IF	CITATIONS
91	Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 3927-3940.	3.3	27
92	Complement component C3aR constitutes a novel regulator for chick eye morphogenesis. <i>Developmental Biology</i> , 2017, 428, 88-100.	0.9	8
93	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. <i>Immunobiology</i> , 2016, 221, 1046-1057.	0.8	14
94	Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. <i>EMBO Journal</i> , 2016, 35, 1133-1149.	3.5	123
95	Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16027.	2.0	11
96	Complement in disease: a defence system turning offensive. <i>Nature Reviews Nephrology</i> , 2016, 12, 383-401.	4.1	427
97	Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex. <i>Journal of Infectious Diseases</i> , 2016, 214, 140-150.	1.9	13
98	Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. <i>Seminars in Immunology</i> , 2016, 28, 285-291.	2.7	44
99	Structural insights into cofactor activity. <i>Immunobiology</i> , 2016, 221, 1193.	0.8	0
100	Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation. <i>Immunobiology</i> , 2016, 221, 1216.	0.8	0
101	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. <i>Clinical Immunology</i> , 2016, 171, 32-35.	1.4	23
102	High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. <i>Molecular Cancer Research</i> , 2016, 14, 953-965.	1.5	38
103	Complement therapeutics. <i>Seminars in Immunology</i> , 2016, 28, 205-207.	2.7	12
104	Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. <i>Journal of Immunology</i> , 2016, 197, 2500-2508.	0.4	22
105	More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. <i>Immunological Reviews</i> , 2016, 274, 233-244.	2.8	104
106	Protection of host cells by complement regulators. <i>Immunological Reviews</i> , 2016, 274, 152-171.	2.8	173
107	Preformed mediators of defense "Gatekeepers enter the spotlight. <i>Immunological Reviews</i> , 2016, 274, 5-8.	2.8	4
108	Complement component C3 "The "Swiss Army Knife" of innate immunity and host defense. <i>Immunological Reviews</i> , 2016, 274, 33-58.	2.8	313

#	ARTICLE	IF	CITATIONS
109	Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. <i>Journal of Clinical Periodontology</i> , 2016, 43, 238-249.	2.3	55
110	Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherin. <i>Developmental Biology</i> , 2016, 414, 85-99.	0.9	22
111	New milestones ahead in complement-targeted therapy. <i>Seminars in Immunology</i> , 2016, 28, 208-222.	2.7	92
112	Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. <i>Journal of Immunology</i> , 2016, 196, 4671-4680.	0.4	35
113	Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. <i>Clinical Immunology</i> , 2016, 162, 37-44.	1.4	14
114	Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. <i>Journal of Immunology</i> , 2016, 196, 866-876.	0.4	37
115	Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. <i>Molecular Oral Microbiology</i> , 2016, 31, 3-17.	1.3	36
116	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. <i>Immunobiology</i> , 2016, 221, 503-511.	0.8	28
117	Therapeutic control of complement activation at the level of the central component C3. <i>Immunobiology</i> , 2016, 221, 740-746.	0.8	41
118	Complement inhibition decreases early fibrogenic events in the lung of septic baboons. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 2549-2563.	1.6	36
119	Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1207-1217.	1.8	38
120	Interventional treatment of renal angiomyolipoma: immediate results and clinical and radiological follow-up of 4.5 years. <i>Acta Radiologica Open</i> , 2015, 4, 205846011559244.	0.3	11
121	Complement Deficiency Promotes Cutaneous Wound Healing in Mice. <i>Journal of Immunology</i> , 2015, 194, 1285-1291.	0.4	58
122	PTX3 Is an Extrinsic Oncosuppressor Regulating Complement-Dependent Inflammation in Cancer. <i>Cell</i> , 2015, 160, 700-714.	13.5	334
123	Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. <i>Journal of Leukocyte Biology</i> , 2015, 98, 539-548.	1.5	96
124	Complement Inhibition in a Xenogeneic Model of Interactions Between Human Whole Blood and Porcine Endothelium. <i>Hormone and Metabolic Research</i> , 2015, 47, 36-42.	0.7	17
125	Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. <i>Immunobiology</i> , 2015, 220, 993-998.	0.8	49
126	Inhibition of the alternative complement pathway preserves photoreceptors after retinal injury. <i>Science Translational Medicine</i> , 2015, 7, 297ra116.	5.8	58

#	ARTICLE	IF	CITATIONS
127	Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2015, 126, 891-894.	0.6	89
128	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. <i>Immunobiology</i> , 2015, 220, 476-482.	0.8	58
129	Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. <i>Molecular Therapy</i> , 2015, 23, 1066-1076.	3.7	65
130	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. <i>Journal of Immunology</i> , 2015, 194, 3305-3316.	0.4	23
131	Regulation of Instant Blood Mediated Inflammatory Reaction (IBMIR) in Pancreatic Islet Xeno-Transplantation: Points for Therapeutic Interventions. <i>Advances in Experimental Medicine and Biology</i> , 2015, 865, 171-188.	0.8	25
132	Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. <i>European Journal of Clinical Investigation</i> , 2015, 45, 423-440.	1.7	178
133	Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2015, 865, 57-74.	0.8	53
134	A Phase-Variable Surface Layer from the Gut Symbiont <i>Bacteroides thetaiotaomicron</i> . <i>MBio</i> , 2015, 6, e01339-15.	1.8	14
135	Applying complement therapeutics to rare diseases. <i>Clinical Immunology</i> , 2015, 161, 225-240.	1.4	60
136	Attenuation of <i>Staphylococcus aureus</i> -Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. <i>Journal of Immunology</i> , 2015, 195, 3946-3958.	0.4	9
137	A 'rule of 3' to revive Greek science, research and innovation. <i>Nature Immunology</i> , 2015, 16, 1206-1208.	7.0	2
138	Acute Lung Injury and Fibrosis in a Baboon Model of <i>Escherichia coli</i> Sepsis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 439-450.	1.4	30
139	T cell-derived interleukin (IL)-21 promotes brain injury following stroke in mice. <i>Journal of Experimental Medicine</i> , 2014, 211, 595-604.	4.2	85
140	Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration. <i>Human Molecular Genetics</i> , 2014, 23, 52-68.	1.4	47
141	The Extracellular Adherence Protein from <i>Staphylococcus aureus</i> Inhibits the Classical and Lectin Pathways of Complement by Blocking Formation of the C3 Proconvertase. <i>Journal of Immunology</i> , 2014, 193, 6161-6171.	0.4	51
142	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. <i>Expert Review of Hematology</i> , 2014, 7, 583-598.	1.0	43
143	Conjugation to Albumin-Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. <i>ChemMedChem</i> , 2014, 9, 2223-2226.	1.6	13
144	The Role of Complement in Tumor Growth. <i>Advances in Experimental Medicine and Biology</i> , 2014, 772, 229-262.	0.8	155

#	ARTICLE	IF	CITATIONS
145	Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. <i>Biomaterials</i> , 2014, 35, 3688-3696.	5.7	40
146	Crosstalk between the coagulation and complement systems in sepsis. <i>Thrombosis Research</i> , 2014, 133, S28-S31.	0.8	114
147	Do Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties?. <i>Stem Cells</i> , 2014, 32, 2430-2442.	1.4	300
148	The alternative complement pathway regulates pathological angiogenesis in the retina. <i>FASEB Journal</i> , 2014, 28, 3171-3182.	0.2	54
149	Post challenge inhibition of C3 and CD14 attenuates <i>Escherichia coli</i> induced inflammation in human whole blood. <i>Innate Immunity</i> , 2014, 20, 68-77.	1.1	17
150	Cholesterol Crystals Induce Complement-Dependent Inflammasome Activation and Cytokine Release. <i>Journal of Immunology</i> , 2014, 192, 2837-2845.	0.4	236
151	A Murine Rp1 Missense Mutation Causes Protein Mislocalization and Slowly Progressive Photoreceptor Degeneration. <i>American Journal of Pathology</i> , 2014, 184, 2721-2729.	1.9	18
152	Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. <i>Journal of Immunology</i> , 2014, 192, 6020-6027.	0.4	97
153	<i>Porphyromonas gingivalis</i> Manipulates Complement and TLR Signaling to Uncouple Bacterial Clearance from Inflammation and Promote Dysbiosis. <i>Cell Host and Microbe</i> , 2014, 15, 768-778.	5.1	318
154	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014, 123, 2094-2101.	0.6	172
155	The Evolution and Appearance of C3 Duplications in Fish Originate an Exclusive Teleost c3 Gene Form with Anti-Inflammatory Activity. <i>PLoS ONE</i> , 2014, 9, e99673.	1.1	54
156	Distinct role of complement anaphylatoxin receptors C5aR and C3aR in obese adipose tissue inflammation and insulin resistance. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, .	0.6	1
157	Complement inhibition in cancer therapy. <i>Seminars in Immunology</i> , 2013, 25, 54-64.	2.7	121
158	Inhibition of biomaterial-induced complement activation attenuates the inflammatory host response to implantation. <i>FASEB Journal</i> , 2013, 27, 2768-2776.	0.2	35
159	Inducing and Characterizing Liver Regeneration in Mice: Reliable Models, Essential Readouts and Critical Perspectives. <i>Current Protocols in Mouse Biology</i> , 2013, 3, 141-170.	1.2	4
160	CMAP: Complement Map Database. <i>Bioinformatics</i> , 2013, 29, 1832-1833.	1.8	26
161	Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms. <i>Journal of Immunology</i> , 2013, 190, 3831-3838.	0.4	412
162	The role of the complement system in metabolic organs and metabolic diseases. <i>Seminars in Immunology</i> , 2013, 25, 47-53.	2.7	126

#	ARTICLE	IF	CITATIONS
163	Complement in Immune and Inflammatory Disorders: Therapeutic Interventions. <i>Journal of Immunology</i> , 2013, 190, 3839-3847.	0.4	209
164	Does complement play a role in bone development and regeneration?. <i>Immunobiology</i> , 2013, 218, 1-9.	0.8	45
165	C5L2 receptor disruption enhances the development of diet-induced insulin resistance in mice. <i>Immunobiology</i> , 2013, 218, 127-133.	0.8	33
166	Progress and Trends in Complement Therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	0.8	107
167	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. <i>Immunobiology</i> , 2013, 218, 496-505.	0.8	129
168	Role of complement in host-microbe homeostasis of the periodontium. <i>Seminars in Immunology</i> , 2013, 25, 65-72.	2.7	75
169	Cholesterol crystals activate the complement system and are phagocytosed in a complement-dependent manner. <i>Molecular Immunology</i> , 2013, 56, 246.	1.0	1
170	C1-inhibitor efficiently inhibits <i>Escherichia coli</i> -induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. <i>Clinical and Experimental Immunology</i> , 2013, 173, 217-229.	1.1	22
171	Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 301-313.	0.8	9
172	Complement-triggered pathways orchestrate regenerative responses throughout phylogenesis. <i>Seminars in Immunology</i> , 2013, 25, 29-38.	2.7	72
173	The induction of cytokines by polycation containing microspheres by a complement dependent mechanism. <i>Biomaterials</i> , 2013, 34, 621-630.	5.7	35
174	Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. <i>Biomaterials</i> , 2013, 34, 985-994.	5.7	50
175	Induction of Complement C3a Receptor Responses by Kallikrein-Related Peptidase 14. <i>Journal of Immunology</i> , 2013, 191, 3858-3866.	0.4	24
176	A Structurally Dynamic N-terminal Helix Is a Key Functional Determinant in Staphylococcal Complement Inhibitor (SCIN) Proteins. <i>Journal of Biological Chemistry</i> , 2013, 288, 2870-2881.	1.6	16
177	Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. <i>Nature Communications</i> , 2013, 4, 2312.	5.8	80
178	Complement modulates the cutaneous microbiome and inflammatory milieu. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15061-15066.	3.3	138
179	The Complement Anaphylatoxin C5a Receptor Contributes to Obese Adipose Tissue Inflammation and Insulin Resistance. <i>Journal of Immunology</i> , 2013, 191, 4367-4374.	0.4	97
180	Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties. <i>Journal of Immunology</i> , 2013, 190, 5712-5721.	0.4	137

#	ARTICLE	IF	CITATIONS
181	Complement-Targeted Therapeutics in Periodontitis. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 197-206.	0.8	17
182	The Effects of Selective Complement and CD14 Inhibition on the E. coli-Induced Tissue Factor mRNA Upregulation, Monocyte Tissue Factor Expression, and Tissue Factor Functional Activity in Human Whole Blood. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 123-136.	0.8	20
183	Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2013, 122, 1239-1239.	0.6	1
184	Regulation of Immune Responsiveness In Vivo By Disrupting an Early T-Cell Signaling Event Using a Cell-Permeable Peptide. <i>PLoS ONE</i> , 2013, 8, e63645.	1.1	7
185	Progress and trends in complement therapeutics. <i>Advances in Experimental Medicine and Biology</i> , 2013, 735, 1-22.	0.8	11
186	A sweet spot to control complement-induced inflammation. <i>Nature Medicine</i> , 2012, 18, 1340-1341.	15.2	6
187	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. <i>Journal of Immunology</i> , 2012, 189, 4797-4805.	0.4	50
188	Correction: Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. <i>Journal of Immunology</i> , 2012, 188, 6425-6425.	0.4	2
189	Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. <i>Journal of Immunology</i> , 2012, 189, 4674-4683.	0.4	219
190	Diversity in the C3b contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.. <i>Journal of Biological Chemistry</i> , 2012, 287, 9329.	1.6	0
191	The Role of Properdin in Zymosan- and <i>Escherichia coli</i> -Induced Complement Activation. <i>Journal of Immunology</i> , 2012, 189, 2606-2613.	0.4	38
192	Diversity in the C3b Convertase Contact Residues and Tertiary Structures of the Staphylococcal Complement Inhibitor (SCIN) Protein Family. <i>Journal of Biological Chemistry</i> , 2012, 287, 628-640.	1.6	26
193	Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis. <i>Circulation Research</i> , 2012, 110, 1202-1210.	2.0	172
194	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. <i>Journal of Immunology</i> , 2012, 189, 5442-5448.	0.4	100
195	Immune competence of the <i>Ciona intestinalis</i> pharynx: Complement system-mediated activity. <i>Fish and Shellfish Immunology</i> , 2012, 33, 946-952.	1.6	34
196	Complement and dysbiosis in periodontal disease. <i>Immunobiology</i> , 2012, 217, 1111-1116.	0.8	97
197	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. <i>Immunobiology</i> , 2012, 217, 1097-1105.	0.8	39
198	Preface. <i>Immunobiology</i> , 2012, 217, 1025.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Autoregulation of thromboinflammation on biomaterials and cells by a novel therapeutic coating technique. <i>Immunobiology</i> , 2012, 217, 1140.	0.8	0
200	Complement anaphylatoxin C5a supports ovarian cancer development and controls the expression of VEGF164/165 isoforms. <i>Immunobiology</i> , 2012, 217, 1155.	0.8	0
201	Complement in action: An analysis of patent trends from 1976 through 2011. <i>Immunobiology</i> , 2012, 217, 1157-1158.	0.8	0
202	Complement pathways in periodontitis and targeted therapeutic intervention. <i>Immunobiology</i> , 2012, 217, 1159.	0.8	0
203	Complement receptor C3aR modulates platelet function and thrombosis. <i>Immunobiology</i> , 2012, 217, 1160.	0.8	0
204	Compstatin induces allosteric changes in C3 and C3b and changes their ligand binding pattern. <i>Immunobiology</i> , 2012, 217, 1160.	0.8	0
205	On the conformational flexibility of C3b: A molecular insight into activation and transformation of a major complement effector. <i>Immunobiology</i> , 2012, 217, 1192.	0.8	0
206	Phagocytosis of <i>Escherichia coli</i> in human whole blood: Early complement dependency is succeeded by late CD14 dependency over time. <i>Immunobiology</i> , 2012, 217, 1193.	0.8	0
207	The role of properdin in zymosan- and <i>Escherichia coli</i> -induced complement activation. <i>Immunobiology</i> , 2012, 217, 1212.	0.8	0
208	Poly-cation containing alginate microcapsules induce cytokines by a complement-dependent mechanism. <i>Immunobiology</i> , 2012, 217, 1221.	0.8	3
209	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. <i>Neoplasia</i> , 2012, 14, 994-IN1.	2.3	103
210	A Complement-IL-4 Regulatory Circuit Controls Liver Regeneration. <i>Journal of Immunology</i> , 2012, 188, 641-648.	0.4	52
211	Absence of Mannose-Binding Lectin Prevents Hyperglycemic Cardiovascular Complications. <i>American Journal of Pathology</i> , 2012, 180, 104-112.	1.9	23
212	Pathogenic Microbes and Community Service Through Manipulation of Innate Immunity. <i>Advances in Experimental Medicine and Biology</i> , 2012, 946, 69-85.	0.8	43
213	Advances in Understanding the Structure, Function, and Mechanism of the SCIN and Efb Families of Staphylococcal Immune Evasion Proteins. <i>Advances in Experimental Medicine and Biology</i> , 2012, 946, 113-133.	0.8	31
214	C5a antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. <i>Journal of Orthopaedic Research</i> , 2012, 30, 581-586.	1.2	41
215	Interactions between coagulation and complement—their role in inflammation. <i>Seminars in Immunopathology</i> , 2012, 34, 151-165.	2.8	393
216	Novel Complement Modulators for Paroxysmal Nocturnal Hemoglobinuria: Peptide and Protein Inhibitors of C3 Convertase Prevent Both Surface C3 Deposition and Subsequent Hemolysis of Affected Erythrocytes in Vitro. <i>Blood</i> , 2012, 120, 370-370.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Low-Abundance Biofilm Species Orchestrates Inflammatory Periodontal Disease through the Commensal Microbiota and Complement. <i>Cell Host and Microbe</i> , 2011, 10, 497-506.	5.1	916
218	Complement Fragment C3a Controls Mutual Cell Attraction during Collective Cell Migration. <i>Developmental Cell</i> , 2011, 21, 1026-1037.	3.1	271
219	Synthesis and Activity of Thioether-Containing Analogues of the Complement Inhibitor Compstatin. <i>ACS Chemical Biology</i> , 2011, 6, 753-760.	1.6	70
220	Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses. <i>PLoS ONE</i> , 2011, 6, e21703.	1.1	135
221	The Anaphylatoxin Receptor C5aR Is Present During Fracture Healing in Rats and Mediates Osteoblast Migration In Vitro. <i>Journal of Trauma</i> , 2011, 71, 952-960.	2.3	60
222	Microbial manipulation of receptor crosstalk in innate immunity. <i>Nature Reviews Immunology</i> , 2011, 11, 187-200.	10.6	256
223	Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. <i>Molecular Immunology</i> , 2011, 48, 481-489.	1.0	62
224	<i>Ornithodoros moubata</i> complement inhibitor (OmCI) is an equally effective C5 inhibitor in pig and human, and combined with CD14 inhibition, efficiently attenuate <i>Escherichia coli</i> -induced sepsis in pigs. <i>Molecular Immunology</i> , 2011, 48, 1699.	1.0	0
225	<i>Neisseria meningitidis</i> and <i>Escherichia coli</i> are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. <i>Molecular Immunology</i> , 2011, 48, 2159-2169.	1.0	20
226	G protein coupled receptor specificity for C3a and compound 48/80-induced degranulation in human mast cells: Roles of Mas-related genes MrgX1 and MrgX2. <i>European Journal of Pharmacology</i> , 2011, 668, 299-304.	1.7	98
227	Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person. <i>Annals of Thoracic Surgery</i> , 2011, 91, 527-533.	0.7	17
228	Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1042-1050.	6.6	163
229	Blood protein-polymer adsorption: Implications for understanding complement-mediated hemoincompatibility. <i>Journal of Biomedical Materials Research - Part A</i> , 2011, 97A, 74-84.	2.1	48
230	Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1 β . <i>Journal of Cellular Biochemistry</i> , 2011, 112, 2594-2605.	1.2	142
231	Protection of Nonself Surfaces from Complement Attack by Factor H-Binding Peptides: Implications for Therapeutic Medicine. <i>Journal of Immunology</i> , 2011, 186, 4269-4277.	0.4	85
232	Immune Evasion of <i>Moraxella catarrhalis</i> Involves Ubiquitous Surface Protein A-Dependent C3d Binding. <i>Journal of Immunology</i> , 2011, 186, 3120-3129.	0.4	24
233	Early post-operative measurement of cytokine plasma levels combined with pre-operative bilirubin levels identify high-risk patients after liver resection. <i>International Journal of Molecular Medicine</i> , 2011, 27, 447-54.	1.8	18
234	PMX-53 as a Dual CD88 Antagonist and an Agonist for Mas-Related Gene 2 (MrgX2) in Human Mast Cells. <i>Molecular Pharmacology</i> , 2011, 79, 1005-1013.	1.0	89

#	ARTICLE	IF	CITATIONS
235	Activation of Polymorphonuclear Leukocytes by Candidate Biomaterials for an Implantable Glucose Sensor. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1490-1498.	1.3	11
236	<i>Ornithodoros moubata</i> Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. <i>Journal of Immunology</i> , 2011, 187, 4913-4919.	0.4	40
237	The C5a Receptor Impairs IL-12-Dependent Clearance of <i>Porphyromonas gingivalis</i> and Is Required for Induction of Periodontal Bone Loss. <i>Journal of Immunology</i> , 2011, 186, 869-877.	0.4	149
238	Complement inhibition decreases the fibrotic response in septic baboons. <i>FASEB Journal</i> , 2011, 25, 114.7.	0.2	0
239	Abstract 2413: Diet-induced non-alcoholic steatohepatitis and hepatocellular carcinoma in chromosome substitution strains of mice. , 2011, , .		0
240	A complement receptor C5a antagonist regulates epithelial to mesenchymal transition and crystallin expression after lens cataract surgery in mice. <i>Molecular Vision</i> , 2011, 17, 949-64.	1.1	14
241	Hypoxia and reoxygenation of primary human hepatocytes induce proteome changes of glucose metabolism, oxidative protection and peroxisomal function. <i>International Journal of Molecular Medicine</i> , 2010, 26, 577-84.	1.8	14
242	Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. <i>Blood</i> , 2010, 116, 4395-4403.	0.6	174
243	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. <i>Blood</i> , 2010, 116, 631-639.	0.6	124
244	Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of <i>Escherichia coli</i> sepsis. <i>Blood</i> , 2010, 116, 1002-1010.	0.6	159
245	Key role of CD14 in the <i>E. coli</i> - and LPS-induced mRNA down regulation of the C5a receptors CD88 and C5L2. <i>Molecular Immunology</i> , 2010, 47, 2241-2241.	1.0	0
246	Characterization of the interactions between C3b and complement regulators. <i>Molecular Immunology</i> , 2010, 47, 2259-2259.	1.0	0
247	Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. <i>European Journal of Immunology</i> , 2010, 40, 1355-1368.	1.6	87
248	Multi-scale characterization of the energy landscape of proteins with application to the C3D/Efb complex. <i>Proteins: Structure, Function and Bioinformatics</i> , 2010, 78, 1004-1014.	1.5	5
249	Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. <i>Periodontology 2000</i> , 2010, 52, 141-162.	6.3	66
250	An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. <i>Gene Therapy</i> , 2010, 17, 752-762.	2.3	36
251	Complement: a key system for immune surveillance and homeostasis. <i>Nature Immunology</i> , 2010, 11, 785-797.	7.0	2,990
252	Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity. <i>Innate Immunity</i> , 2010, 16, 254-264.	1.1	12

#	ARTICLE	IF	CITATIONS
253	<i>In Vivo</i> Significance of ITK-SLP-76 Interaction in Cytokine Production. <i>Molecular and Cellular Biology</i> , 2010, 30, 3596-3609.	1.1	20
254	Complement Component C3 Binds to Activated Normal Platelets without Preceding Proteolytic Activation and Promotes Binding to Complement Receptor 1. <i>Journal of Immunology</i> , 2010, 184, 2686-2692.	0.4	100
255	Allosteric inhibition of complement function by a staphylococcal immune evasion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 17621-17626.	3.3	77
256	Molecular Intercommunication between the Complement and Coagulation Systems. <i>Journal of Immunology</i> , 2010, 185, 5628-5636.	0.4	605
257	Microbial Hijacking of Complementâ€“Toll-Like Receptor Crosstalk. <i>Science Signaling</i> , 2010, 3, ra11.	1.6	177
258	Structures of C3b in Complex with Factors B and D Give Insight into Complement Convertase Formation. <i>Science</i> , 2010, 330, 1816-1820.	6.0	241
259	Selective inhibition of TNF-Î± or IL-1Î² does not affect E. coli-induced inflammation in human whole blood. <i>Molecular Immunology</i> , 2010, 47, 1774-1782.	1.0	11
260	Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. <i>Molecular Immunology</i> , 2010, 47, 2222-2222.	1.0	0
261	Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?. <i>Trends in Immunology</i> , 2010, 31, 32-38.	2.9	119
262	Crosstalk pathways between Toll-like receptors and the complement system. <i>Trends in Immunology</i> , 2010, 31, 154-163.	2.9	248
263	Molecular Basis for Complement Recognition and Inhibition Determined by Crystallographic Studies of the Staphylococcal Complement Inhibitor (SCIN) Bound to C3c and C3b. <i>Journal of Molecular Biology</i> , 2010, 402, 17-29.	2.0	39
264	Suppression of Drusen Formation by Compstatin, a Peptide Inhibitor of Complement C3 activation, on Cynomolgus Monkey with Early-Onset Macular Degeneration. <i>Advances in Experimental Medicine and Biology</i> , 2010, 703, 127-135.	0.8	59
265	Contribution of Chondroitin Sulfate A to the Binding of Complement Proteins to Activated Platelets. <i>PLoS ONE</i> , 2010, 5, e12889.	1.1	42
266	A flow-through optical sensor system for label-free detection of proteins and DNA. , 2009, , .		1
267	Complement-Dependent Neutrophil Recruitment Is Critical for the Development of Elastase-Induced Abdominal Aortic Aneurysm. <i>Circulation</i> , 2009, 119, 1805-1813.	1.6	95
268	A Molecular Insight into Complement Evasion by the Staphylococcal Complement Inhibitor Protein Family. <i>Journal of Immunology</i> , 2009, 183, 2565-2574.	0.4	63
269	C3 Promotes Expansion of CD8+ and CD4+ T Cells in a <i>Listeria monocytogenes</i> Infection. <i>Journal of Immunology</i> , 2009, 183, 2921-2931.	0.4	42
270	The Regulation of Liver Cell Survival by Complement. <i>Journal of Immunology</i> , 2009, 182, 5412-5418.	0.4	91

#	ARTICLE	IF	CITATIONS
271	Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15861-15866.	3.3	119
272	Unwelcome Complement. <i>Cancer Research</i> , 2009, 69, 6367-6370.	0.4	50
273	Diet-induced hepatocellular carcinoma in genetically predisposed mice. <i>Human Molecular Genetics</i> , 2009, 18, 2975-2988.	1.4	142
274	Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. <i>Brain Research</i> , 2009, 1298, 171-177.	1.1	75
275	Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. <i>Journal of Molecular Recognition</i> , 2009, 22, 495-505.	1.1	48
276	Complement and Neutrophil Function Changes After Liver Resection in Humans. <i>World Journal of Surgery</i> , 2009, 33, 2635-2643.	0.8	8
277	Crystallization of human complement component C3b in the presence of a staphylococcal complement-inhibitor protein (SCIN). <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 482-485.	0.7	10
278	C3a Receptor Antagonist Attenuates Brain Injury after Intracerebral Hemorrhage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 98-107.	2.4	73
279	Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. <i>Nature Immunology</i> , 2009, 10, 728-733.	7.0	299
280	Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. <i>Nature Immunology</i> , 2009, 10, 721-727.	7.0	205
281	Real-time label-free detection of complement activation products in human serum by white light reflectance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2009, 24, 3359-3364.	5.3	17
282	Is complement good or bad for cancer patients? A new perspective on an old dilemma. <i>Trends in Immunology</i> , 2009, 30, 286-292.	2.9	123
283	Key role of complement receptor 1 in the initial binding of <i>Escherichia coli</i> and <i>Neisseria meningitidis</i> to erythrocytes in human whole blood. <i>Molecular Immunology</i> , 2009, 46, 2824.	1.0	0
284	Binding of complement proteins to activated platelets is independent of complement activation. <i>Molecular Immunology</i> , 2009, 46, 2853.	1.0	0
285	Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood. <i>Molecular Immunology</i> , 2009, 46, 2911-2917.	1.0	29
286	Recent developments in low molecular weight complement inhibitors. <i>Molecular Immunology</i> , 2009, 47, 185-195.	1.0	96
287	Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects. <i>Journal of Immunology</i> , 2009, 183, 6724-6732.	0.4	37
288	Diet-induced hepatocellular carcinoma in genetically predisposed mice. <i>FASEB Journal</i> , 2009, 23, LB508.	0.2	0

#	ARTICLE	IF	CITATIONS
289	The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. <i>Journal of Biomedical Materials Research - Part A</i> , 2008, 87A, 129-135.	2.1	40
290	Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2008, 19, 55-65.	1.2	20
291	Development of a New Pharmacophore Model That Discriminates Active Compstatin Analogs. <i>Chemical Biology and Drug Design</i> , 2008, 72, 249-256.	1.5	11
292	Modulation of the antitumor immune response by complement. <i>Nature Immunology</i> , 2008, 9, 1225-1235.	7.0	612
293	Complement evasion by human pathogens. <i>Nature Reviews Microbiology</i> , 2008, 6, 132-142.	13.6	654
294	Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1413-1421.	1.9	127
295	Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. <i>Xenotransplantation</i> , 2008, 15, 225-234.	1.6	121
296	ciCD94-1, an ascidian multipurpose C-type lectin-like receptor expressed in <i>Ciona intestinalis</i> hemocytes and larval neural structures. <i>Differentiation</i> , 2008, 76, 267-282.	1.0	26
297	Complexity of complement activation in sepsis. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2245-2254.	1.6	109
298	Electrostatic contributions drive the interaction between <i>Staphylococcus aureus</i> protein Efb and its complement target C3d. <i>Protein Science</i> , 2008, 17, 1894-1906.	3.1	34
299	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. <i>Journal of Surgical Research</i> , 2008, 150, 196-203.	0.8	22
300	Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. <i>Molecular Immunology</i> , 2008, 45, 3142-3151.	1.0	19
301	Novel insights into target specificities and molecular mechanisms for two potent complement evasion proteins from <i>Staphylococcus aureus</i> . <i>Molecular Immunology</i> , 2008, 45, 4114-4115.	1.0	0
302	Genetic complement deficiencies dissociate the roles of human complement in the inflammatory responses: Lessons from nature. <i>Molecular Immunology</i> , 2008, 45, 4145-4146.	1.0	0
303	A C3 inhibitor on its way to clinical applications: Novel developments in compstatin activity and function. <i>Molecular Immunology</i> , 2008, 45, 4180.	1.0	0
304	Identification of complement-targeting peptides using phage-display libraries. <i>Molecular Immunology</i> , 2008, 45, 4180-4181.	1.0	1
305	C5a and TNF- α Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome. <i>Journal of Immunology</i> , 2008, 180, 7368-7375.	0.4	115
306	Compstatin: A Complement Inhibitor on its Way to Clinical Application. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 262-281.	0.8	139

#	ARTICLE	IF	CITATIONS
307	Interaction Between the Coagulation and Complement System. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 68-76.	0.8	329
308	Cytokine Secretion Depends on Gal α 1(3)Gal Expression in a Pig-to-Human Whole Blood Model. <i>Journal of Immunology</i> , 2008, 180, 6346-6353.	0.4	28
309	Cutting Edge: Members of the <i>Staphylococcus aureus</i> Extracellular Fibrinogen-Binding Protein Family Inhibit the Interaction of C3d with Complement Receptor 2. <i>Journal of Immunology</i> , 2008, 181, 7463-7467.	0.4	54
310	Stages of Meningococcal Sepsis Simulated In Vitro, with Emphasis on Complement and Toll-Like Receptor Activation. <i>Infection and Immunity</i> , 2008, 76, 4183-4189.	1.0	38
311	Ceruloplasmin/Hephaestin Knockout Mice Model Morphologic and Molecular Features of AMD. , 2008, 49, 2728.		117
312	Acute Antibody-Mediated Complement Activation Mediates Lysis of Pancreatic Islets Cells and May Cause Tissue Loss in Clinical Islet Transplantation. <i>Transplantation</i> , 2008, 85, 1193-1199.	0.5	73
313	Characterization of Ehp, a Secreted Complement Inhibitory Protein from <i>Staphylococcus aureus</i> . <i>Journal of Biological Chemistry</i> , 2007, 282, 30051-30061.	1.6	84
314	Complement Deposits on Ocular Tissues Adjacent to Sites of Inflammation. <i>Current Eye Research</i> , 2007, 32, 917-922.	0.7	14
315	C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ischemia/Reperfusion. <i>Journal of Immunology</i> , 2007, 178, 1819-1828.	0.4	104
316	Structure of Compstatin in Complex with Complement Component C3c Reveals a New Mechanism of Complement Inhibition. <i>Journal of Biological Chemistry</i> , 2007, 282, 29241-29247.	1.6	116
317	Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. <i>Blood</i> , 2007, 110, 228-236.	0.6	327
318	The Classical Complement Cascade Mediates CNS Synapse Elimination. <i>Cell</i> , 2007, 131, 1164-1178.	13.5	2,567
319	Complement and coagulation: strangers or partners in crime?. <i>Trends in Immunology</i> , 2007, 28, 184-192.	2.9	533
320	The role of complement in biomaterial-induced inflammation. <i>Molecular Immunology</i> , 2007, 44, 82-94.	1.0	384
321	DAF/Cry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. <i>Molecular Immunology</i> , 2007, 44, 139-146.	1.0	20
322	Structure-activity-based design of potent compstatin analogs. <i>Molecular Immunology</i> , 2007, 44, 192.	1.0	0
323	First identification of a chemotactic receptor in an invertebrate species: Structural and functional characterization of <i>Ciona intestinalis</i> C3a receptor. <i>Molecular Immunology</i> , 2007, 44, 238-239.	1.0	0
324	Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin, and alternative pathways of complement. <i>Molecular Immunology</i> , 2007, 44, 254.	1.0	0

#	ARTICLE	IF	CITATIONS
325	Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. <i>Molecular Immunology</i> , 2007, 44, 1819-1826.	1.0	51
326	The C-terminus of complement factor H is essential for host cell protection. <i>Molecular Immunology</i> , 2007, 44, 2697-2706.	1.0	95
327	A novel complement evasion mechanism of <i>Staphylococcus aureus</i> using Efb. <i>Molecular Immunology</i> , 2007, 44, 3926.	1.0	0
328	The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight. <i>American Journal of Pathology</i> , 2007, 171, 715-727.	1.9	563
329	New Approaches to the Treatment of Dense Deposit Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2447-2456.	3.0	231
330	A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1638-1644.	1.4	11
331	Complement-targeted therapeutics. <i>Nature Biotechnology</i> , 2007, 25, 1265-1275.	9.4	427
332	A structural basis for complement inhibition by <i>Staphylococcus aureus</i> . <i>Nature Immunology</i> , 2007, 8, 430-437.	7.0	148
333	CD59 Efficiently Protects Human NT2â€œNeurons Against Complementâ€œmediated Damage. <i>Scandinavian Journal of Immunology</i> , 2007, 66, 345-351.	1.3	14
334	Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 571-580.	1.3	12
335	Exploring the Complement Interaction Network Using Surface Plasmon Resonance. , 2007, 598, 260-278.		16
336	Ancient Origin of the Complement System: Emerging Invertebrate Models. , 2007, 598, 372-388.		45
337	Hydrogen/Deuterium Exchange Mass Spectrometry: Potential for Investigating Innate Immunity Proteins. , 2007, 598, 407-417.		6
338	Liver Regeneration: A Link to Inflammation through Complement. , 2006, 586, 17-34.		22
339	Hydrophobic Effect and Hydrogen Bonds Account for the Improved Activity of a Complement Inhibitor, Compstatin. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4616-4622.	2.9	100
340	To Regeneration ... with Complement. <i>Advances in Experimental Medicine and Biology</i> , 2006, 586, 63-70.	0.8	12
341	Liver inflammation and regeneration: Two distinct biological phenomena or parallel pathophysiologic processes?. <i>Molecular Immunology</i> , 2006, 43, 45-56.	1.0	82
342	Compstatin inhibits complement activation by binding to the β 2-chain of complement factor 3. <i>Molecular Immunology</i> , 2006, 43, 2023-2029.	1.0	25

#	ARTICLE	IF	CITATIONS
343	Expression of compstatin in Escherichia coli: Incorporation of unnatural amino acids enhances its activity. Protein Expression and Purification, 2006, 47, 289-295.	0.6	18
344	Generation of C5a in the absence of C3: a new complement activation pathway. Nature Medicine, 2006, 12, 682-687.	15.2	845
345	Structure of C3b reveals conformational changes that underlie complement activity. Nature, 2006, 444, 213-216.	13.7	344
346	A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 852-857.	2.5	48
347	Drusen complement components C3a and C5a promote choroidal neovascularization. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2328-2333.	3.3	584
348	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
349	Pathogenesis of B-Cell Superantigen-Induced Immune Complex-Mediated Inflammation. Infection and Immunity, 2006, 74, 1196-1203.	1.0	19
350	160. Innate Immune Responses to Viral Vectors Are Modulated by Complement Inhibitors in an Ex Vivo Model Using Whole Human Blood. Molecular Therapy, 2006, 13, S62-S63.	3.7	0
351	First Identification of a Chemotactic Receptor in an Invertebrate Species: Structural and Functional Characterization of <i>Ciona intestinalis</i> C3a Receptor. Journal of Immunology, 2006, 177, 4132-4140.	0.4	37
352	Cross-Disciplinary Research Stirs New Challenges into the Study of the Structure, Function and Systems Biology of Complement. Advances in Experimental Medicine and Biology, 2006, 586, 1-16.	0.8	4
353	The Role of Third Complement Component (C3) in Homing of Hematopoietic Stem/Progenitor Cells into Bone Marrow. , 2006, 586, 35-51.		20
354	A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. Journal of Clinical Investigation, 2006, 116, 783-796.	3.9	194
355	Thrombin as a C5 Convertase. FASEB Journal, 2006, 20, A641.	0.2	0
356	Structure-Based Integrative Computational and Experimental Approach for the Optimization of Drug Design. Lecture Notes in Computer Science, 2005, , 680-688.	1.0	10
357	Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface. Biomaterials, 2005, 26, 1477-1485.	5.7	171
358	C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. European Journal of Immunology, 2005, 35, 2496-2506.	1.6	125
359	A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF- κ B inhibitor, I κ B ζ . Hepatology, 2005, 42, 1148-1157.	3.6	125
360	Partial hepatectomy induced liver proteome changes in mice. Proteomics, 2005, 5, 318-325.	1.3	43

#	ARTICLE	IF	CITATIONS
361	Mechanisms of Action of Differentiation Inducers: Detection of Inducer Binding Protein(s) in Murine Erythroleukemia Cells. <i>Oncology Research</i> , 2005, 15, 21-37.	0.6	1
362	Electrostatic Modeling Predicts the Activities of Orthopoxvirus Complement Control Proteins. <i>Journal of Immunology</i> , 2005, 174, 2143-2151.	0.4	73
363	Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1392-1403.	3.0	354
364	Solvent Accessibility of Native and Hydrolyzed Human Complement Protein 3 Analyzed by Hydrogen/Deuterium Exchange and Mass Spectrometry. <i>Journal of Immunology</i> , 2005, 174, 3469-3474.	0.4	26
365	Complement: An Inflammatory Pathway Fulfilling Multiple Roles at the Interface of Innate Immunity and Development. <i>Inflammation and Allergy: Drug Targets</i> , 2005, 4, 125-127.	3.1	24
366	The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. <i>Journal of Experimental Medicine</i> , 2005, 201, 567-577.	4.2	212
367	Complement Component C5a Is Integral to the Febrile Response of Mice to Lipopolysaccharide. <i>NeuroImmunoModulation</i> , 2005, 12, 67-80.	0.9	28
368	Design and NMR Characterization of Active Analogues of Compstatin Containing Non-Natural Amino Acids. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 274-286.	2.9	68
369	Novel biological networks modulated by complement. <i>Clinical Immunology</i> , 2005, 115, 225-235.	1.4	42
370	Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production. <i>Annals of Thoracic Surgery</i> , 2005, 79, 917-923.	0.7	30
371	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		4
372	Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues. , 2005, , 317-340.		3
373	Structure of the Anaphylatoxins C3a and C5a. , 2005, , 161-177.		0
374	The Building Blocks of the Complement System. , 2005, , 1-18.		1
375	Complement Activation Is Critical to Airway Hyperresponsiveness after Acute Ozone Exposure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 726-732.	2.5	52
376	The Electrostatic Nature of C3d-Complement Receptor 2 Association. <i>Journal of Immunology</i> , 2004, 172, 7537-7547.	0.4	48
377	Complement C5a Receptor Is Essential for the Optimal Generation of Antiviral CD8+ T Cell Responses. <i>Journal of Immunology</i> , 2004, 173, 2524-2529.	0.4	97
378	Thermodynamic Studies on the Interaction of the Third Complement Component and Its Inhibitor, Compstatin. <i>Journal of Biological Chemistry</i> , 2004, 279, 54987-54995.	1.6	24

#	ARTICLE	IF	CITATIONS
379	C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury. <i>Journal of Immunology</i> , 2004, 173, 747-754.	0.4	155
380	Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. <i>Journal of Neuroimmunology</i> , 2004, 155, 55-63.	1.1	119
381	Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. <i>Virology</i> , 2004, 325, 425-431.	1.1	115
382	Design of Peptide Analogues with Improved Activity Using a Novel de Novo Protein Design Approach. <i>Industrial & Engineering Chemistry Research</i> , 2004, 43, 3817-3826.	1.8	56
383	Dysregulation of Stathmin, a Microtubule-Destabilizing Protein, and Up-Regulation of Hsp25, Hsp27, and the Antioxidant Peroxiredoxin 6 in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. <i>American Journal of Pathology</i> , 2004, 165, 1701-1718.	1.9	90
384	Physical methods for structure, dynamics and binding in immunological research. <i>Trends in Immunology</i> , 2004, 25, 700-707.	2.9	29
385	Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. <i>Molecular Immunology</i> , 2004, 40, 1213-1221.	1.0	57
386	From atoms to systems: a cross-disciplinary approach to complement-mediated functions*1. <i>Molecular Immunology</i> , 2004, 41, 153-164.	1.0	10
387	Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. <i>Annals of Thoracic Surgery</i> , 2004, 77, 932-941.	0.7	68
388	A Functional C5a Anaphylatoxin Receptor in a Teleost Species. <i>Journal of Immunology</i> , 2004, 172, 349-355.	0.4	26
389	Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. <i>Biochemical Society Transactions</i> , 2004, 32, 28-32.	1.6	34
390	Synthetic small-molecule complement inhibitors. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1164-73.	2.3	28
391	Complement: Structure, Functions, Evolution, and Viral Molecular Mimicry. <i>Immunologic Research</i> , 2003, 27, 367-386.	1.3	53
392	Conformational interconversion in compstatin probed with molecular dynamics simulations. <i>Proteins: Structure, Function and Bioinformatics</i> , 2003, 53, 130-141.	1.5	23
393	Molecular cloning of the β_2 subunit of complement component eight of rainbow trout. <i>Developmental and Comparative Immunology</i> , 2003, 27, 167-174.	1.0	34
394	Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. <i>Molecular Immunology</i> , 2003, 39, 557-566.	1.0	81
395	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. <i>Clinical Immunology</i> , 2003, 108, 263-273.	1.4	53
396	Restoration of Complement-Enhanced Neutralization of Vaccinia Virus Virions by Novel Monoclonal Antibodies Raised against the Vaccinia Virus Complement Control Protein. <i>Journal of Virology</i> , 2003, 77, 8256-8262.	1.5	27

#	ARTICLE	IF	CITATIONS
397	Expression of Complement 3 and Complement 5 in Newt Limb and Lens Regeneration. <i>Journal of Immunology</i> , 2003, 170, 2331-2339.	0.4	130
398	Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection. <i>Journal of Immunology</i> , 2003, 170, 788-794.	0.4	105
399	The Proinflammatory Mediators C3a and C5a Are Essential for Liver Regeneration. <i>Journal of Experimental Medicine</i> , 2003, 198, 913-923.	4.2	385
400	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Open Reading Frame 4 Protein (Kaposica) Is a Functional Homolog of Complement Control Proteins. <i>Journal of Virology</i> , 2003, 77, 3878-3881.	1.5	60
401	CiC3-1a-Mediated Chemotaxis in the Deuterostome Invertebrate <i>Ciona intestinalis</i> (Urochordata). <i>Journal of Immunology</i> , 2003, 171, 5521-5528.	0.4	76
402	Integrated Computational and Experimental Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity. <i>Journal of the American Chemical Society</i> , 2003, 125, 8422-8423.	6.6	85
403	Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression. <i>Journal of Immunology</i> , 2003, 170, 503-507.	0.4	301
404	Studies of Structure-Activity Relations of Complement Inhibitor Compstatin. <i>Journal of Immunology</i> , 2003, 171, 1881-1890.	0.4	39
405	Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. <i>Blood</i> , 2003, 101, 3784-3793.	0.6	217
406	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. <i>Journal of Clinical Investigation</i> , 2003, 112, 1644-1654.	3.9	266
407	Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. <i>Journal of Clinical Investigation</i> , 2003, 112, 1644-1654.	3.9	537
408	Protection of innate immunity by C5aR antagonist in septic mice. <i>FASEB Journal</i> , 2002, 16, 1567-1574.	0.2	152
409	Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10837-10842.	3.3	417
410	Role of Membrane Cofactor Protein (CD46) in Regulation of C4b and C3b Deposited on Cells. <i>Journal of Immunology</i> , 2002, 168, 6298-6304.	0.4	123
411	Expression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells. <i>Journal of Immunology</i> , 2002, 169, 5962-5970.	0.4	145
412	Herpes Simplex Virus Type 1 Evades the Effects of Antibody and Complement In Vivo. <i>Journal of Virology</i> , 2002, 76, 9232-9241.	1.5	91
413	Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. <i>Blood</i> , 2002, 100, 4544-4549.	0.6	44
414	Structural aspects and design of low-molecular-mass complement inhibitors. <i>Biochemical Society Transactions</i> , 2002, 30, 1026-1036.	1.6	49

#	ARTICLE	IF	CITATIONS
415	The complement system in teleosts. <i>Fish and Shellfish Immunology</i> , 2002, 12, 399-420.	1.6	511
416	Complement: more than a "guard"™ against invading pathogens?. <i>Trends in Immunology</i> , 2002, 23, 485-491.	2.9	144
417	Innate immunity in the Aegean: ancient pathways for today's survival. <i>Developmental and Comparative Immunology</i> , 2002, 26, 217-225.	1.0	14
418	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. <i>Journal of Biological Chemistry</i> , 2002, 277, 14942-14953.	1.6	50
419	Complement in urochordates: cloning and characterization of two C3-like genes in the ascidian <i>Ciona intestinalis</i> . <i>Immunogenetics</i> , 2002, 53, 1055-1064.	1.2	90
420	Kinetic Analysis of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 Binding to Heparin, Heparan Sulfate, and Complement Component C3b. <i>Virology</i> , 2002, 294, 324-332.	1.1	68
421	Increased C5a receptor expression in sepsis. <i>Journal of Clinical Investigation</i> , 2002, 110, 101-108.	3.9	141
422	Increased C5a receptor expression in sepsis. <i>Journal of Clinical Investigation</i> , 2002, 110, 101-108.	3.9	103
423	Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. <i>Blood</i> , 2002, 100, 1869-77.	0.6	342
424	Cloning and structure of three rainbow trout C3 molecules: a plausible explanation for their functional diversity. <i>Developmental and Comparative Immunology</i> , 2001, 25, 11-24.	1.0	76
425	Cloning and purification of the rainbow trout fifth component of complement (C5). <i>Developmental and Comparative Immunology</i> , 2001, 25, 419-430.	1.0	54
426	Phylogenetic aspects of the complement system. <i>Developmental and Comparative Immunology</i> , 2001, 25, 745-762.	1.0	118
427	Structural Studies in Solution of the Recombinant N-Terminal Pair of Short Consensus/Complement Repeat Domains of Complement Receptor Type 2 (CR2/CD21) and Interactions with Its Ligand C3dg. <i>Biochemistry</i> , 2001, 40, 5931-5941.	1.2	55
428	Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. <i>Immunological Reviews</i> , 2001, 180, 35-48.	2.8	449
429	Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface. <i>Journal of Immunology</i> , 2001, 167, 5758-5766.	0.4	49
430	Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220. <i>Journal of Immunology</i> , 2001, 167, 1490-1499.	0.4	72
431	A Novel Role of Complement: Mice Deficient in the Fifth Component of Complement (C5) Exhibit Impaired Liver Regeneration. <i>Journal of Immunology</i> , 2001, 166, 2479-2486.	0.4	220
432	HUMAN SERUM-INDUCED EXPRESSION OF E-SELECTIN ON PORCINE AORTIC ENDOTHELIAL CELLS IN VITRO IS TOTALLY COMPLEMENT MEDIATED1. <i>Transplantation</i> , 2001, 72, 1967-1973.	0.5	24

#	ARTICLE	IF	CITATIONS
433	Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. <i>Immunopharmacology</i> , 2000, 49, 133-148.	2.0	147
434	Complement and innate immunity. <i>Immunopharmacology</i> , 2000, 49, 187-198.	2.0	112
435	Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin. <i>Journal of Immunology</i> , 2000, 165, 2491-2499.	0.4	105
436	Novel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1. <i>Journal of Immunology</i> , 2000, 165, 4528-4536.	0.4	56
437	The three HveA receptor ligands, gD, LT- β and LIGHT bind to distinct sites on HveA. <i>Molecular Immunology</i> , 2000, 37, 665-673.	1.0	36
438	Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model. <i>Transplantation Proceedings</i> , 2000, 32, 899-900.	0.3	6
439	Inhibition of Heparin/Protamine Complex-Induced Complement Activation by Compstatin in Baboons. <i>Clinical Immunology</i> , 2000, 96, 212-221.	1.4	68
440	In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc. <i>Journal of Experimental Medicine</i> , 1999, 190, 1637-1646.	4.2	108
441	Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 628-633.	3.3	149
442	Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. <i>Xenotransplantation</i> , 1999, 6, 52-65.	1.6	90
443	Contribution of the Innate Immune System to Autoimmune Diabetes: A Role for the CR1/CR2 Complement Receptors. <i>Cellular Immunology</i> , 1999, 195, 75-79.	1.4	36
444	Prolongation of ex vivo perfused pig xenograft survival by the complement inhibitor compstatin. <i>Transplantation Proceedings</i> , 1999, 31, 934-935.	0.3	26
445	Inhibition of Herpes Simplex Virus gD and Lymphotoxin- β Binding to HveA by Peptide Antagonists. <i>Journal of Virology</i> , 1999, 73, 5681-5687.	1.5	13
446	Evolution and diversity of the complement system of poikilothermic vertebrates. <i>Immunological Reviews</i> , 1998, 166, 39-57.	2.8	155
447	Structure, functions, and evolution of the third complement component and viral molecular mimicry. <i>Immunologic Research</i> , 1998, 17, 109-121.	1.3	27
448	Solution structure of Compstatin, a potent complement inhibitor. <i>Protein Science</i> , 1998, 7, 619-627.	3.1	87
449	Complement diversity: a mechanism for generating immune diversity?. <i>Trends in Immunology</i> , 1998, 19, 519-523.	7.5	158
450	Cloning of three trout C3 isoforms: structural, functional, and phylogenetic analysis. <i>Molecular Immunology</i> , 1998, 35, 370.	1.0	3

#	ARTICLE	IF	CITATIONS
451	Expression of the third component of complement, C3, in regenerating limb blastema cells of urodeles. <i>Molecular Immunology</i> , 1998, 35, 372.	1.0	6
452	Inhibition of complement and xenogeneic endothelial cell activation by compstatin. <i>Molecular Immunology</i> , 1998, 35, 372.	1.0	0
453	Mass spectrometric analysis of the activation and expression products of the third component of complement (C3). <i>Molecular Immunology</i> , 1998, 35, 373.	1.0	0
454	Herpes Simplex Virus Glycoprotein D Can Bind to Poliovirus Receptor-Related Protein 1 or Herpesvirus Entry Mediator, Two Structurally Unrelated Mediators of Virus Entry. <i>Journal of Virology</i> , 1998, 72, 7064-7074.	1.5	223
455	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. <i>Blood</i> , 1998, 92, 1661-1667.	0.6	133
456	Herpes Simplex Virus Type 1 Glycoprotein gC Mediates Immune Evasion In Vivo. <i>Journal of Virology</i> , 1998, 72, 8257-8263.	1.5	97
457	Structural and Antigenic Analysis of a Truncated Form of the Herpes Simplex Virus Glycoprotein gH-gL Complex. <i>Journal of Virology</i> , 1998, 72, 6092-6103.	1.5	68
458	The Chemistry and Biology of C3, C4 and C5. , 1998, , 83-118.		42
459	Compstatin Inhibits Complement and Cellular Activation in Whole Blood in Two Models of Extracorporeal Circulation. <i>Blood</i> , 1998, 92, 1661-1667.	0.6	6
460	Diversity of the third form of complement, C3, in fish: functional characterization of five forms of C3 in the diploid fish <i>Sparus aurata</i> . <i>Biochemical Journal</i> , 1997, 326, 877-881.	1.7	95
461	Differentiation-dependent changes in human trophoblast expression of decay-accelerating factor are modulated by 3',5' cyclic adenosine monophosphate. <i>Journal of the Society for Gynecologic Investigation</i> , 1997, 4, 47-53.	1.9	4
462	Structural Change in α -Chymotrypsin Induced by Complexation with α -1-Antichymotrypsin As Seen by Enhanced Sensitivity to Proteolysis. <i>Biochemistry</i> , 1996, 35, 10608-10615.	1.2	81
463	Multiple forms of complement C3 in trout that differ in binding to complement activators.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 8546-8551.	3.3	141
464	Mass spectrometric analyses of the activation products of the third component of complement. <i>Techniques in Protein Chemistry</i> , 1996, 7, 81-91.	0.3	0
465	Immune evasion properties of herpes simplex virus type 1 glycoprotein gC. <i>Journal of Virology</i> , 1996, 70, 4253-4260.	1.5	96
466	The third component of <i>Xenopus</i> complement: cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript. <i>European Journal of Immunology</i> , 1995, 25, 572-578.	1.6	29
467	Effect of a Putative B Cell Superantigen on Complement. <i>Annals of the New York Academy of Sciences</i> , 1995, 764, 356-358.	1.8	3
468	The Interaction of Glycoprotein C of Herpes Simplex Virus Types 1 and 2 with the Alternative Complement Pathway. <i>Virology</i> , 1994, 203, 299-312.	1.1	61

#	ARTICLE	IF	CITATIONS
469	Overexpression, purification, and characterization of third component of complement. <i>Journal of Immunological Methods</i> , 1994, 176, 127-139.	0.6	11
470	Phylogeny of the Third Complement Component, C3, and Conservation of C3-Ligand Interactions. <i>Annals of the New York Academy of Sciences</i> , 1994, 712, 354-357.	1.8	6
471	Hormonal regulation of complement components and receptors throughout the menstrual cycle. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 170, 168-175.	0.7	78
472	Hormonal regulation of complement components and receptors throughout the menstrual cycle. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 170, 168-175.	0.7	63
473	Expression of EBV/C3d receptors on T cells: biological significance. <i>Trends in Immunology</i> , 1993, 14, 56-59.	7.5	82
474	Hormonal Regulation of Complement Factor B in Human Endometrium. <i>American Journal of Reproductive Immunology</i> , 1993, 30, 63-67.	1.2	26
475	Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. <i>Biochemical Journal</i> , 1992, 282, 715-721.	1.7	22
476	Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. <i>Developmental and Comparative Immunology</i> , 1992, 16, 63-76.	1.0	63
477	Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. <i>Biochemistry</i> , 1992, 31, 1787-1794.	1.2	40
478	Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. <i>European Journal of Immunology</i> , 1992, 22, 1123-1131.	1.6	25
479	Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor). <i>J Immunol</i> 1992; 149: 4314-4319.	1.6	45
480	Infection of human thymocytes by Epstein-Barr virus. <i>Journal of Experimental Medicine</i> , 1991, 173, 971-980.	4.2	136
481	Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. <i>Biochemical Journal</i> , 1990, 268, 55-61.	1.7	31
482	Isolation and characterization of the third complement component of axolotl (<i>Ambystoma</i>). <i>J Immunol</i> 1990; 145: 839-845.	0.2	5
483	Cell Surface Proteins Reacting with Activated Complement Components. <i>Complement and Inflammation</i> , 1989, 6, 142-165.	0.8	43
484	Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. <i>EMBO Journal</i> , 1989, 8, 1947-1952.	3.5	69
485	The Central Segment of Herpes Simplex Virus Type 1 Glycoprotein C (gC) Is Not Involved in C3b Binding: Demonstration by Using Monoclonal Antibodies and Recombinant gC Expressed in <i>Escherichia coli</i> . <i>Journal of General Virology</i> , 1989, 70, 1571-1578.	1.3	23
486	Isolation of rat IgM to IgG hybridoma isotype switch variants and analysis of the efficiency of rat Ig in complement activation. <i>European Journal of Immunology</i> , 1989, 19, 131-135.	1.6	26

#	ARTICLE	IF	CITATIONS
487	Peptides of myelin basic protein stimulate T lymphocytes from patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1989, 22, 23-30.	1.1	39
488	A role for Lys-His-Gly-NH ₂ in avian and murine B cell development. <i>Cellular Immunology</i> , 1989, 122, 319-328.	1.4	23
489	Accumulation of viruslike particles in a yeast mutant lacking a mitochondrial pore protein.. <i>Molecular and Cellular Biology</i> , 1989, 9, 1100-1108.	1.1	38
490	Conservation of structural and functional domains in complement component C3 of <i>Xenopus</i> and mammals.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 1323-1327.	3.3	43
491	Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.. <i>Journal of Clinical Investigation</i> , 1989, 83, 1794-1799.	3.9	59
492	Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. <i>European Journal of Immunology</i> , 1988, 18, 1299-1302.	1.6	105
493	The multifunctional role of C3, the third component of complement. <i>Trends in Immunology</i> , 1988, 9, 387-393.	7.5	223
494	Functional maturation of murine B lymphocyte precursorsâ€”III. Soluble factors involved in the regulation of growth and differentiation. <i>Molecular Immunology</i> , 1988, 25, 1113-1127.	1.0	8
495	Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-CS antibodies. <i>Molecular and Cellular Probes</i> , 1987, 1, 141-149.	0.9	82
496	Similarities between a conserved sequence element of homoeo boxes and other genes. <i>FEBS Letters</i> , 1986, 194, 263-266.	1.3	2
497	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. <i>Immunopharmacology and Immunotoxicology</i> , 1986, 8, 529-541.	1.1	5
498	The multifunctional role of C3: Structural analysis of its interactions with physiological ligands. <i>Molecular Immunology</i> , 1986, 23, 1237-1242.	1.0	23
499	Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. <i>Biochemical Journal</i> , 1986, 233, 613-616.	1.7	75
500	Complement Receptors (CR) and Cytotoxic Responses: Monoclonal Antibodies Directed Against CR1 AMD CR3 Inhibit the Generation of Human Allospecific and Virus Specific Cytotoxic Cells in Vitro. <i>Immunopharmacology and Immunotoxicology</i> , 1986, 8, 75-88.	1.1	0
501	Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. <i>Biochemical Journal</i> , 1985, 232, 841-850.	1.7	93
502	Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 4235-4239.	3.3	98
503	Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.. <i>Journal of Clinical Investigation</i> , 1985, 76, 1418-1426.	3.9	52
504	Lymphocyte mitogenesis induced by monoclonal antibodies to the T3 complex. Differential modulation by human IgG. <i>Cellular Immunology</i> , 1984, 89, 66-74.	1.4	20

#	ARTICLE	IF	CITATIONS
505	Mapping of the properdin-binding site in the third component of complement. <i>Biochemical Journal</i> , 1984, 217, 323-326.	1.7	32
506	Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. <i>Biochemical Journal</i> , 1984, 224, 389-398.	1.7	116
507	Coupling of C3b to erythrocytes by disulfide bond formation: Preparation of EC3b for hemolytic and complement receptor assays. <i>Journal of Immunological Methods</i> , 1983, 65, 277-283.	0.6	13
508	Importance of Factors H and I for the Adherence of C3b-Coated Erythrocytes to Cells. <i>Immunobiology</i> , 1983, 165, 211-224.	0.8	3
509	Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 Fragments for Factors B and H, complement receptors, and bovine conglutinin. <i>Journal of Experimental Medicine</i> , 1983, 158, 334-352.	4.2	166
510	Identification of a C3bi-specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils, and erythrocytes. <i>Journal of Experimental Medicine</i> , 1982, 155, 96-110.	4.2	176
511	Activation of the Alternative Pathway of Human Complement by the Extracellular Slime Glycolipoprotein of <i>Pseudomonas aeruginosa</i> . <i>Journal of Infectious Diseases</i> , 1982, 145, 78-82.	1.9	10
512	Identification of three forms of iC3b that have distinct structures and receptor binding site properties. <i>Molecular Immunology</i> , 1982, 19, 1399.	1.0	4
513	Characterization of the lymphocyte membrane receptor for factor H (125 I-H globulin) with an antibody to anti-factor H idiotype. <i>Journal of Experimental Medicine</i> , 1982, 155, 1400-1411.	4.2	61
514	In vivo changes in complement induced with peptidoglycan-polysaccharide polymers from streptococcal cell walls. <i>Infection and Immunity</i> , 1982, 35, 377-380.	1.0	29
515	Isolation of lymphocyte membrane complement receptor type two (the C3d receptor) and preparation of receptor-specific antibody.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1981, 78, 1828-1832.	3.3	71
516	Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for beta 1H globulin.. <i>Journal of Experimental Medicine</i> , 1980, 152, 1625-1644.	4.2	137
517	Protein component of <i>Pseudomonas aeruginosa</i> slime glycolipoprotein in relation to laboratory-induced resistance to gentamicin. <i>Canadian Journal of Microbiology</i> , 1980, 26, 852-853.	0.8	1
518	A method for analysing lymphocyte surface antigens. <i>Journal of Immunological Methods</i> , 1980, 34, 287-293.	0.6	7
519	Fluorescent labelling of proteins of lymphocyte plasma membranes. <i>Journal of Immunological Methods</i> , 1979, 27, 55-59.	0.6	3
520	Complement as a target in COVID-19?. , 0, .		1
521	Complement Inhibitors Targeting C3, C4, and C5. , 0, , 75-112.		10